Getinge (OTCPK:GNGB.F) - Aandelenkoers, Nieuws & Analyse

GNGB.F Overzicht aandelen

Getinge AB (publ) levert producten en oplossingen voor operatiekamers, intensive-care-units en sterilisatieafdelingen. Meer informatie

GNGB.F fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	3/6
Prestaties in het verleden	2/6
Financiële gezondheid	6/6
Dividenden	4/6

Beloningen

Verhandeld tegen 50.9% onder onze schatting van de reële waarde

De winst zal naar verwachting met 22.02% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Onstabiel dividend track record

Winstmarges (5%) zijn lager dan vorig jaar (7.4%)

Getinge AB (publ) Concurrenten

Integer Holdings

NYSE:ITGR

US$4.5b

LivaNova

NasdaqGS:LIVN

US$2.8b

CONMED

NYSE:CNMD

US$2.2b

LeMaitre Vascular

NasdaqGM:LMAT

US$2.3b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Getinge
Historische aandelenkoersen
Huidige aandelenkoers	SEK 17.00
52 Week Hoogtepunt	SEK 22.39
52 Week Laag	SEK 17.00
Bèta	0.49
11 maand verandering	-15.55%
3 maanden verandering	n/a
1 Jaar Verandering	-15.03%
33 jaar verandering	-63.26%
5 jaar verandering	n/a
Verandering sinds IPO	49.08%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	GNGB.F	US Medical Equipment	US Markt
7D	-4.8%	-0.7%	-2.1%
1Y	-15.0%	22.5%	29.7%

Rendement versus industrie: GNGB.F presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 22.5 % opleverde.

Rendement versus markt: GNGB.F presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 29.7 % opleverde.

Prijsvolatiliteit

Is GNGB.F's price volatile compared to industry and market?
GNGB.F volatility
GNGB.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van GNGB.F is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van GNGB.F in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1904	11,848	Mattias Perjos	www.getinge.com

Getinge AB (publ) levert producten en oplossingen voor operatiekamers, intensive-care-units en sterilisatieafdelingen. Het bedrijf opereert via de segmenten Acute Care Therapies, Life Science en Surgical Workflows. Het bedrijf biedt extracorporale membraanoxygenatie, mechanische beademing, mechanische circulatieondersteuning, geavanceerde patiëntbewaking, ICU-infrastructuurapparatuur, patiëntenstroombeheer en drainageoplossingen.

Getinge AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Getinge zich tot de beurswaarde?
GNGB.F fundamentele statistieken
Marktkapitalisatie	US$4.47b
Inkomsten(TTM)	US$153.88m
Inkomsten(TTM)	US$3.06b

29.1x

Koers/Winstverhouding

1.5x

P/S-verhouding

Is GNGB.F overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GNGB.F resultatenrekening (TTM)
Inkomsten	SEK 33.59b
Kosten van inkomsten	SEK 18.21b
Brutowinst	SEK 15.39b
Overige uitgaven	SEK 13.69b
Inkomsten	SEK 1.69b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Jan 28, 2025

Winst per aandeel (EPS)	6.21
Brutomarge	45.80%
Nettowinstmarge	5.03%
Schuld/Eigen Vermogen Verhouding	30.0%

Hoe presteerde GNGB.F op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.4%

Huidig dividendrendement

71%

Uitbetalingsratio

GNGB.F Overzicht aandelen

Beloningen

Risicoanalyse

Getinge AB (publ) Concurrenten

NYSE:ITGR

US$4.5b

NasdaqGS:LIVN

US$2.8b

NYSE:CNMD

US$2.2b

NasdaqGM:LMAT

US$2.3b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Recent updates

Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Getinge AB (Publ) Proposes Dividend

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Getinge Appoints Agneta Palmér as Executive Vice President Operational Services Member of the Getinge Executive Team

Getinge AB (publ) to Report Q2, 2022 Results on Jul 19, 2022

Lena Hagman to Leave Getinge AB (publ) as Executive Vice President Quality Compliance, Regulatory & Medical Affairs

Getinge Revises Net Sales Guidance for the Full Year 2022

Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022

Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.

Getinge AB Provides Sales Guidance for the Year 2021

Getinge's New Torin Artificial Intelligence Solution Improves Hospital Efficiency

Getinge AB Proposes Dividend, Payable on April 27, 2021

Getinge AB and University of Gothenburg Initiates Strategic Research Partnership

Getinge AB Proposes Executive Changes

Getinge Is Announcing A Recall of HLS Set Advanced Products

Getinge AB Provides No Guidance for the Fourth Quarter of 2020 and for Year 2021

Getinge Not to Present Outlook for the Full Year 2020

Getinge Announces Ventilation Technology for Both Premature Babies and Adults

Getinge AB to Report Q3, 2020 Results on Oct 16, 2020

Getinge Announces Voluntary Recall of the Servo-i Ventilator System's Nebulizer Connector

Getinge AB Appoints Anna Romberg as Executive Vice President Legal, Compliance & Governance and Member, with Effect from October 01, 2020